[Whitepaper] Personalized Test for Treatment Prediction in Depression

Psychiatry remains without a single personalized test to predict treatment response or remission in Depression.

Major Depressive Disorder is one of the most common psychiatric disorders in the US, with over 15 million people impacted and costing $100 billion annually, of which less than half achieve symptom remission with the first medication tried. The cost associated with a prolonged duration of depressive symptoms is substantial, including lower employment levels and higher risk for a range of other general medical conditions.

Total Brain’s aim in undertaking the iSPOT-D study (International Study to Predict Optimized Treatment in Depression) was to develop the first objective Personalized Medicine Test to determine who is more and less likely to respond to three of the most common antidepressant medications.

Across the three antidepressants (n = 1,008 patients), the iSPOT-D Test has an Accuracy of 79-84%, PPV: 70-74%, and NPV of 84-92%

Primary Care Physicians (PCPs), Psychiatrists and other clinicians face daily challenges of objective decision making for treatment options in Depression. This test has the potential to greatly benefit these decisions with unprecedented objective information.

Learn more about the details of the study and its results in this whitepaper.


Presented by: